Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

CompletedOBSERVATIONAL

Enrollment

467

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Non-Melanoma Skin Carcinoma

Interventions

DRUG

voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

OTHER

no voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.